Thanks for joining DividendStocks.com, the daily newsletter built for dividend and income investors like you. We’re thrilled to have you on board and can’t wait to help you discover the best dividend opportunities out there. Before we can start sending your daily insights, please take a quick moment to confirm your subscription: Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Why wait? Let’s get your dividend journey started! Click Here to Start Discovering Top Income-Generating Stocks See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
This Month's Exclusive News A Fresh IPO That Long-Term Investors Shouldn't IgnoreAuthor: Jordan Chussler. First Published: 1/14/2026. 
What You Need to Know - While IPOs are often labeled as high-risk startups, some are worthy of more conservative investors’ attention.
- Aktis Oncology’s IPO—the first biotech IPO of 2026—resulted in a $318 million raise, with the biotech firm receiving $100 million in backing from Big Pharma giant Eli Lilly.
- The company, which now has a market cap of $3.34 billion, develops radiopharmaceuticals and is positioned for long-term success after being listed on the Nasdaq.
For speculative investors, the start of each year is a good time to revisit an initial public offering (IPO) calendar. Almost every week, companies go public, and a handful often offer considerable short-term upside potential. Of course, IPOs also carry substantial downside risk. But even conservative investors who favor caution shouldn't dismiss every recent listing—some newly public stocks can still deserve a place in buy-and-hold portfolios. Most people treat crypto like a lottery ticket, buying low and hoping for a miracle. My special guest this week does the opposite. They use a strategy designed to generate cash flow from volatility itself, regardless of whether the market moves up, down, or sideways. This brand new 2026 workshop reveals a framework that has produced a verified 93 percent win rate across nearly 2,500 documented trade alerts. Attendees also receive $10 in Bitcoin and a copy-paste trade setup just for showing up. Register now to see how disciplined automation beats guessing. For one biotechnology company in the healthcare sector that just went public, that may be precisely the case. Last Year's IPO Success Stories Last year provides a strong example of why newly public companies shouldn't be dismissed by investors with lower risk tolerance. AI cloud computing provider CoreWeave (NASDAQ: CRWV), which went public in March 2025, is up nearly 123% since then. Short-term speculators may have captured its nearly 359% gain within the first 30 days on Nasdaq, but longer-term holders are still enjoying strong returns. Others, such as Medline (NASDAQ: MDLN), refute the misconception that IPOs are all high-risk startups. The medical products and services provider, which publicly debuted in December 2025, was founded in 1966 and already carries a market cap in excess of $55 billion. Similarly, Smithfield Foods (NASDAQ: SFD)—famous for its ubiquitous packages of bacon—waited 89 years before its IPO. Since going public in January 2025, the stock has risen nearly 5%, and it has also rewarded shareholders with a dividend that currently yields 4.44%, or $1 per share annually, making it an immediate consideration for income investors. After its IPO and with shares hitting the market on Jan. 9, Aktis Oncology (NASDAQ: AKTS), a maker of radiopharmaceuticals, is hoping for a similar outcome in 2026 and beyond. Why Are Radiopharmaceuticals Important? Aktis Oncology specializes in radiopharmaceuticals—a subset of nuclear medicine that uses radioactive drugs for diagnostics and treatment of conditions including cancer, heart disease and neurological disorders. Specifically, these drugs combine radioactive isotopes with targeting molecules that seek out particular cells (for example, cancer cells) to deliver localized radiation doses, minimizing harm to healthy tissue compared with conventional radiation therapy. According to industry consultancy Grand View Research, the global nuclear medicine market, estimated at nearly $18 billion in 2024, is forecast to reach nearly $35 billion by 2030—a compound annual growth rate of 10.16%. Importantly for Boston-based Aktis Oncology, Grand View Research notes that the North American segment accounts for nearly 43% of the global nuclear medicine market, with the United States the dominant player. Aktis Oncology's Clinical-Stage Biotechnology Wall Street is expecting biotech IPOs to rebound in 2026 after funding cuts by the Trump administration reportedly slowed healthcare-sector listings in 2025. Aktis Oncology, which debuted on Nasdaq on Jan. 9, was the first biotech IPO of 2026 and produced one of the larger recent biotech raises. With $318 million in IPO proceeds, the firm now has a market cap of about $3.34 billion. According to the company's prospectus, its executive team includes experts in drug development, approval, and commercialization, and management has participated in bringing 14 currently FDA-approved products to market. On a technical level, Aktis develops targeted alpha radiopharmaceuticals, a class of precision cancer drugs that uses proprietary technology to target solid tumors while sparing healthy tissue. Aktis Oncology's Eli Lilly Connection Aktis is a clinical-stage, pre-revenue company, but that did not prevent it from attracting a major strategic partner: Eli Lilly (NYSE: LLY) anchored its IPO. According to Reuters, Eli Lilly purchased $100 million worth of AKTS shares at the IPO. This builds on a partnership struck in 2024 in which Eli Lilly committed $60 million in cash and took an equity stake in Aktis, with potential milestone payments that could exceed $1 billion. The backing from Eli Lilly is significant. With a market cap around $1.01 trillion, Lilly is one of the largest Big Pharma companies, and its net income jumped nearly 109% year-over-year from 2023 to 2024. That performance is likely to remain in focus when Eli Lilly reports Q4 and full-year 2025 financials on Feb. 5. Between its earlier equity stake and the $100 million purchase at the IPO, the maker of Zepbound now has a sizable financial interest in Aktis Oncology's success.
| 
